1326280-86-7

Upstream product

• 55557-52-3 2-chloro-3-cyanopyrazine 
• 939412-86-9 C-(3-chloropyrazin-2-yl)-methylamine hydrochloride salt 
• 3685-26-5 trans-4-hydroxycyclohexanecarboxylic acid 

Downstream Products

• 1419221-25-2 (trans)-4-(8-amino-1-bromoimidazo[1,5-a]pyrazin-3-yl)cyclohexanol 
• 1419221-24-1 (trans)-4-(8-amino-1-bromoimidazol[1,5-a]pyrazin-3-yl)cyclohexyl acetate 
• 1419221-23-0 (trans)-4-(1-bromo-8-chloroimidazo[1,5-a]pyrazin-3-yl)cyclohexyl acetate 
• 1419213-58-3 4-(8-amino-3-((trans)-4-hydroxycyclohexyl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide 
• 1326280-88-9 (trans)-4-((3-chloropyrazin-2-yl)methylcarbamoyl)cyclohexyl acetate 

Relevant academic research and scientific papers

4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors

The present invention provides 6-5 membered fused pyridine ring compounds according to Formula I or pharmaceutically acceptable salts thereof. or a pharmaceutically acceptable salt thereof or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of 6-5 membered fused pyridine ring compounds in the treatment of Bruton's Tyrosine Kinase (Btk) mediated disorders.

8-METHYL-1-PHENYL-IMIDAZOL[1,5-A]PYRAZINE COMPOUNDS

The present invention provides 8-methyl-1 -phenyl-imidazo[1,5-a]pyrazine derivatives according to formula I or pharmaceutically acceptable salts thereof. The compounds of the current invention show inhibitory activity against Lck and can be used for the treatment of Lck-mediated diseases or Lck-mediated conditions such as inflammatory disorders.